Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

0A5R

Calliditas Therapeutics Ab (0A5R)

Calliditas Therapeutics Ab
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0A5R
DateTimeSourceHeadlineSymbolCompany
18/08/202318:21PR Newswire (US)FDA grants priority review for full approval of TARPEYO for the treatment of IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
18/08/202318:17PR Newswire (US)FDA grants priority review for full approval of TARPEYO for the treatment of IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
17/08/202315:29PR Newswire (US)Interim Report Q2, 2023: Calliditas TherapeuticsLSE:0A5RCalliditas Therapeutics Ab
15/08/202318:52PR Newswire (US)Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The LancetLSE:0A5RCalliditas Therapeutics Ab
15/08/202318:50PR Newswire (US)Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The LancetLSE:0A5RCalliditas Therapeutics Ab
13/07/202316:20PR Newswire (US)Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibLSE:0A5RCalliditas Therapeutics Ab
13/07/202316:17PR Newswire (US)Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibLSE:0A5RCalliditas Therapeutics Ab
21/06/202318:12PR Newswire (US)Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®LSE:0A5RCalliditas Therapeutics Ab
21/06/202318:10PR Newswire (US)Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®LSE:0A5RCalliditas Therapeutics Ab
31/05/202300:18PR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
31/05/202300:16PR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
16/05/202315:17PR Newswire (US)Calliditas Therapeutics: Interim Report Q1, 2023LSE:0A5RCalliditas Therapeutics Ab
16/05/202315:14PR Newswire (US)Calliditas Therapeutics: Interim Report Q1, 2023LSE:0A5RCalliditas Therapeutics Ab
05/05/202323:01PR Newswire (US)Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023LSE:0A5RCalliditas Therapeutics Ab
05/05/202323:00PR Newswire (US)Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023LSE:0A5RCalliditas Therapeutics Ab
28/04/202318:54PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
28/04/202318:51PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
27/04/202312:40PR Newswire (US)Calliditas Therapeutics' 2022 Annual Report PublishedLSE:0A5RCalliditas Therapeutics Ab
27/04/202308:15PR Newswire (US)Calliditas Therapeutics' 2022 Annual Report PublishedLSE:0A5RCalliditas Therapeutics Ab
01/04/202302:24PR Newswire (US)Calliditas to participate in upcoming investor conferencesLSE:0A5RCalliditas Therapeutics Ab
01/04/202302:20PR Newswire (US)Calliditas to participate in upcoming investor conferencesLSE:0A5RCalliditas Therapeutics Ab
13/03/202314:15PR Newswire (US)Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
13/03/202314:06PR Newswire (US)Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
23/02/202317:41PR Newswire (US)Calliditas - Year-End Report, 2022LSE:0A5RCalliditas Therapeutics Ab
23/02/202317:34PR Newswire (US)Calliditas - Year-End Report, 2022LSE:0A5RCalliditas Therapeutics Ab
02/02/202319:46PR Newswire (US)Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
02/02/202319:44PR Newswire (US)Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
31/01/202318:22PR Newswire (US)Number of shares and votes in Calliditas TherapeuticsLSE:0A5RCalliditas Therapeutics Ab
30/12/202219:03PR Newswire (US)China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
30/12/202219:00PR Newswire (US)China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
 Showing the most relevant articles for your search:LSE:0A5R